NUVALENT, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 94.00 USD | +0.10% |
|
-0.85% | +27.65% |
| Dec. 09 | Nuvalent, Inc. Appoints Grant Bogle to Board of Directors | CI |
| Dec. 09 | Nuvalent, Inc. Plans to Initiate the Phase 3 Global, Randomized, Controlled ALKAZAR Trial in First Half of 2025 | CI |
Chart calendar Nuvalent, Inc.
577bf9ba0ed99aaa52ac57760296bb5.XoxZc4NaG_8Ym70LwaKNRPOTXSwDCRF9iVxLx9Noqss.JuUTP-oqbZB8_NxlpPPnK7zECmhkMWcN4WwRhKtfn4IN-WE69DFDkirD0g~ef97800cc6e64eb260465e3e08e287ff
Upcoming events on Nuvalent, Inc.
Past events on Nuvalent, Inc.
| 2024-12-03 03:30 pm | Piper Sandler Healthcare Conference |
| 2024-11-19 03:35 pm | Stifel Healthcare Conference |
| 2024-11-13 09:00 am | Guggenheim Securities Healthcare Innovation Conference |
| 2024-11-12 06:30 am | Q3 2024 Earnings Release |
| 2024-09-14 | European Society for Medical Oncology Meeting - Abstract #4811 |
| 2024-09-14 08:30 am | European Society for Medical Oncology Meeting |
| 2024-09-14 04:25 am | European Society for Medical Oncology Meeting - Presentation Number# 1256MO |
| 2024-09-14 03:30 am | European Society for Medical Oncology Meeting - Presentation Number# 1253O |
| 2024-09-05 01:05 pm | Morgan Stanley Healthcare Conference |
| 2024-08-08 06:30 am | Q2 2024 Earnings Release |
| 2024-06-12 01:00 pm | Annual General Meeting |
| 2024-06-05 04:30 pm | Jefferies Global Healthcare Conference - Fireside Chat |
| 2024-05-29 09:30 am | TD Cowen Oncology Innovation Summit |
| 2024-05-09 06:30 am | Q1 2024 Earnings Release |
| 2024-04-08 04:30 pm | American Association for Cancer Research Meeting - Abstract No. LB182 |
| 2024-04-08 12:00 pm | American Association for Cancer Research Meeting - Abstract No. 1979 |
| 2024-03-12 08:00 am | Leerink Partners Global Biopharma Conference - Fireside Chat |
| 2024-03-06 01:30 pm | TD Cowen Health Care Conference - Fireside Chat |
| 2024-02-27 06:30 am | Q4 2023 Earnings Release |
| 2024-02-08 10:30 am | Guggenheim Healthcare Talks Biotechnology Conference |
Annual results
| Fiscal Period | December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 7,50 | 33,7 |
|
EBITDA Million USD | Released Forecast Spread | -45,8 -43,4 -5.69% | -86,1 -78,1 -10.25% | -149 -144 -4.11% | -259 | -344 | -362 |
|
EBIT Million USD | Released Forecast Spread | -45,8 -43,6 -5.17% | -86,1 -79,9 -7.75% | -149 -144 -3.85% | -268 | -335 | -357 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -46,3 -44,2 -4.92% | -81,9 -78,1 -4.76% | -126 -124 -1.53% | -254 | -296 | -311 |
|
Net income Million USD | Released Forecast Spread | -46,3 -43,9 -5.45% | -81,9 -78,2 -4.64% | -126 -125 -0.65% | -257 | -314 | -347 |
|
EPS USD | Released Forecast Spread | -2,13 -1,81 -17.95% | -1,65 -1,56 -5.56% | -2,17 -2,15 -1.04% | -3,93 | -4,67 | -4,98 |
| Announcement Date | 29/03/22 | 16/03/23 | 27/02/24 | - |
Quarterly results
| Fiscal Period | September | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -30,2 -32,0 5.59% | -34,1 -31,0 -9.88% | -38,8 -36,0 -7.73% | -46,4 -41,0 -13.26% | -52,6 -48,0 -9.56% | -65,2 -55,0 -18.45% | -76,3 -67,2 -13.58% | -90,2 | -95,4 | -101 | -107 | -113 |
|
EBIT Million USD | Released Forecast Spread | -30,2 -30,9 2.1% | -34,1 -33,0 -3.34% | -38,8 -36,6 -5.99% | -46,4 -40,9 -13.41% | -52,6 -46,6 -12.83% | -65,2 -52,2 -24.81% | -76,3 -66,3 -15.07% | -78,0 | -78,2 | -81,6 | -85,9 | -96,7 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -25,2 -29,3 13.91% | -29,1 -30,0 3.03% | -33,6 -33,3 -0.97% | -38,3 -37,0 -3.54% | -44,1 -41,0 -7.66% | -57,0 -47,2 -20.63% | -84,3 -60,4 -39.68% | -68,8 | -67,2 | -69,7 | -71,4 | -73,2 |
|
Net income Million USD | Released Forecast Spread | -25,2 -29,3 13.91% | -29,1 -30,5 4.62% | -33,6 -34,0 0.93% | -38,3 -37,8 -1.38% | -44,5 -42,4 -4.79% | -57,2 -49,0 -16.7% | -84,3 -61,9 -36.31% | -71,4 | -70,5 | -74,1 | -79,3 | -85,5 |
|
EPS USD | Released Forecast Spread | -0,44 -0,51 13.99% | -0,51 -0,53 4.59% | -0,59 -0,58 -1.21% | -0,62 -0,60 -3.07% | -0,69 -0,68 -1.45% | -0,88 -0,76 -15.73% | -1,28 -0,93 -37.31% | -1,09 | -1,10 | -1,15 | -1,20 | -1,27 |
| Announcement Date | 11/05/23 | 10/08/23 | 14/11/23 | 27/02/24 | 09/05/24 | 08/08/24 | 12/11/24 | - | - | - | - | - |
More events
Past sector events for Nuvalent, Inc.
| 2024-12-09 06:16 am | LUMOSA THERAPEUTICS CO., LTD.: November 2024 Sales and Revenue Release |
| 2024-12-05 04:03 am | PHARMAESSENTIA CORPORATION: November 2024 Sales and Revenue Release |
| 2024-11-26 04:00 pm | ARROWHEAD PHARMACEUTICALS, INC.: Q4 2024 Earnings Release |
| 2024-11-24 | ANAVEX LIFE SCIENCES CORP.: Q4 2024 Earnings Release (Projected) |
| 2024-11-18 07:00 am | IMMATICS N.V.: Q3 2024 Earnings Release |
| 2024-11-14 04:01 pm | CELCUITY INC.: Q3 2024 Earnings Release |
| 2024-11-14 04:01 pm | ASCENDIS PHARMA A/S: Q3 2024 Earnings Release |
| 2024-11-14 08:00 am | ANNEXON, INC.: Q3 2024 Earnings Release |
| 2024-11-14 04:09 am | PHARMAESSENTIA CORPORATION: Q3 2024 Earnings Release |
| 2024-11-13 | PEPTRON, INC.: Q3 2024 Earnings Release |
Quarterly revenue - Rate of surprise
Net sales - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- NUVL Stock
- Calendar Nuvalent, Inc.